PBE vs. ARKG

In the year-to-date period, PBE achieves a -8.10% return, which is significantly lower than ARKG's -4.65% return. Over the past 10 years, PBE has outperformed ARKG with an annualized return of 1.15%, while ARKG has yielded a comparatively lower 0.42% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

PBE has a 0.59% expense ratio, which is lower than ARKG's 0.75% expense ratio.

This table presents a comparison of risk-adjusted performance metrics for Invesco Dynamic Biotechnology & Genome ETF (PBE) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current PBE Sharpe Ratio is 0.06, which is higher than the ARKG Sharpe Ratio of -0.11. The chart below compares the historical Sharpe Ratios of PBE and ARKG, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

PBE's dividend yield for the trailing twelve months is around 0.07%, while ARKG has not paid dividends to shareholders.

The maximum PBE drawdown since its inception was -45.69%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for PBE and ARKG. For additional features, visit the drawdowns tool.

The current volatility for Invesco Dynamic Biotechnology & Genome ETF (PBE) is 12.54%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 20.64%. This indicates that PBE experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.